The epitope recognized by rituximab

Blood

Volumn 108, Issue 6, 2006, Pages 1975-1978

  Binder, Mascha ^b   Otto, Florian ^b   Mertelsmann, Roland ^b   Veelken, Hendrik ^b   Trepel, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLASPARAGINYLPROLYLSERINE; B LYMPHOCYTE ANTIGEN; CYSTEINYLALANYLLEUCYLMETHIONYLISOLEUCYLALANYLASPARAGINYLSERYLCYSTEINE; CYSTEINYLTRYPTOPHYLTRYPTOPHYLGLUTAMYLTRYPTOPHYLTHREONYLISOLEUCYLGLYCYL CYSTEINE; PEPTIDE; RITUXIMAB; TRYPTOPHYLGLUTAMYLTRYPTOPHYLTHREONYLISOLEUCINE; TYROSYLCYSTEINYLTYROSYLSERYLISOLEUCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNE DISEASE; DISULFIDE BOND; DRUG PROTEIN BINDING; EPITOPE MAPPING; LYMPHOMA; MOLECULAR MIMICRY; MOLECULAR RECOGNITION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MOTIF; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

EID: 33748683352     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-014639     Document Type: Article

References (24)

1. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23:6421-6428.
2. Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol. 2005;23:6394-6399.
3. Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol. 2004;31:17-21.
4. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 2005;4:526-531.
5. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry. 2005;44:15150-15158.
6. Kanzaki M, Lindorfer MA, Garrison JC, Kojima I. Activation of the calcium-permeable cation channel CD20 by alpha subunits of the Gi protein. J Biol Chem. 1997;272:14733-14739.
7. Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem. 1995;270:13099-13104.
8. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26:133-143.
9. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392-1398.
10. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12:S1-S4.
11. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118-129.
12. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99:3256-3262.
13. Perosa F, Favoino E, Caragnano MA, Dammacco F. CD20 Mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann N Y Acad Sci. 2005;1051:672-683.
14. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107:1070-1077.
15. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu: a new method of epitope definition. Mol Immunol. 2005;42:1121-1124.
16. Irving MB, Pan O, Scott JK. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol. 2001;5:314-324.
17. Wang LF, Yu M. Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. Curr Drug Targets. 2004;5:1-15.
18. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003;21:57-63.
19. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol. 1994;124:373-380.
20. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993;217:228-257.
21. Müller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003;21:1040-1046.
22. Tamm I, Trepel M, Cardo-Vila M, et al. Peptides targeting caspase inhibitors. J Biol Chem. 2003;278:14401-14405.
23. Fellouse FA, Wiesmann C, Sidhu SS. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A. 2004;101:12467-12472.
24. Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS. Molecular recognition by a binary code. J Mol Biol. 2005;348:1153-1162.